2024
A single arm phase 2 clinical trial of YIV-906 with neoadjuvant concurrent chemo-radiation therapy in patients with locally advanced rectal cancer
Verma N, Johung K, Kortmansky J, Zaheer W, Lacy J, Cecchini M, Stein S, Cheng Y, Lam W, Liu S, Reddy V, Hochster H, Higgins S. A single arm phase 2 clinical trial of YIV-906 with neoadjuvant concurrent chemo-radiation therapy in patients with locally advanced rectal cancer. Journal Of Gastrointestinal Oncology 2024, 15: 1050-1059. PMID: 38989411, PMCID: PMC11231844, DOI: 10.21037/jgo-24-23.Peer-Reviewed Original ResearchPembrolizumab Plus Binimetinib With or Without Chemotherapy for MSS/pMMR Metastatic Colorectal Cancer: Outcomes From KEYNOTE-651 Cohorts A, C, and E
Chen E, Kavan P, Tehfe M, Kortmansky J, Sawyer M, Chiorean E, Lieu C, Polite B, Wong L, Fakih M, Spencer K, Chaves J, Li C, Leconte P, Adelberg D, Kim R. Pembrolizumab Plus Binimetinib With or Without Chemotherapy for MSS/pMMR Metastatic Colorectal Cancer: Outcomes From KEYNOTE-651 Cohorts A, C, and E. Clinical Colorectal Cancer 2024, 23: 183-193. PMID: 38653648, DOI: 10.1016/j.clcc.2024.03.002.Peer-Reviewed Original ResearchObjective response rateMetastatic colorectal cancerCohort ACohort CCohort EDose escalationInvestigator-assessed objective response rateColorectal cancerResponse rateModified toxicity probability interval designDose reductionSafety findingsPrimary endpointPembrolizumabBinimetinibLeucovorinE. CONCLUSIONSChemotherapyPatientsCohortIrinotecanOxaliplatinCancerInterval designWeeks
2020
The Utility of Neoadjuvant Radiotherapy after Neoadjuvant Multiagent Chemotherapy in Patients with Localized Pancreatic Cancer
Miccio J, Talcott W, Patel T, Park H, Cecchini M, Salem R, Stein S, Kortmansky J, Lacy J, Johung K, Jethwa K. The Utility of Neoadjuvant Radiotherapy after Neoadjuvant Multiagent Chemotherapy in Patients with Localized Pancreatic Cancer. International Journal Of Radiation Oncology • Biology • Physics 2020, 108: e31-e32. DOI: 10.1016/j.ijrobp.2020.02.538.Peer-Reviewed Original ResearchPembrolizumab (pembro) plus mFOLFOX7 or FOLFIRI in patients (pts) with metastatic colorectal cancer (mCRC): Updated results from KEYNOTE-651 cohorts B and D
Kim R, Chaves J, Kavan P, Fakih M, Kortmansky J, Spencer K, Wong L, Tehfe M, Li J, Eyring A, Mayo C, Chiorean E. Pembrolizumab (pembro) plus mFOLFOX7 or FOLFIRI in patients (pts) with metastatic colorectal cancer (mCRC): Updated results from KEYNOTE-651 cohorts B and D. Annals Of Oncology 2020, 31: s450. DOI: 10.1016/j.annonc.2020.08.604.Peer-Reviewed Original Research
2018
O-030 Randomized trial of irinotecan and cetuximab (IC) versus irinotecan, cetuximab and ramucirumab (ICR) as 2nd line therapy of advanced colorectal cancer (CRC) following oxaliplatin and bevacizumb based therapy: Result of E7208
Hochster H, Catalano P, O'Dwyer P, Mitchell E, Cohen D, Faller B, Kortmansky J, Kircher S, Lacy J, Lenz H, Verma U, Benson A, ECOG-ACRIN. O-030 Randomized trial of irinotecan and cetuximab (IC) versus irinotecan, cetuximab and ramucirumab (ICR) as 2nd line therapy of advanced colorectal cancer (CRC) following oxaliplatin and bevacizumb based therapy: Result of E7208. Annals Of Oncology 2018, 29: v110. DOI: 10.1093/annonc/mdy149.029.Peer-Reviewed Original ResearchP-320 Pilot trial of YIV-906 with neoadjuvant chemoradiotherapy (CRT) in patients with locally advanced rectal cancer
Johung K, Kann B, Lacy J, Stein S, Kortmansky J, Zaheer W, Cheng Y, Lam W, Liu S, Decker R, Hochster H, Higgins S. P-320 Pilot trial of YIV-906 with neoadjuvant chemoradiotherapy (CRT) in patients with locally advanced rectal cancer. Annals Of Oncology 2018, 29: v90. DOI: 10.1093/annonc/mdy151.319.Peer-Reviewed Original ResearchRandomized trial of irinotecan and cetuximab (IC) versus irinotecan, cetuximab and ramucirumab (ICR) as 2nd line therapy of advanced colorectal cancer (CRC) following oxaliplatin and bevacizumb based therapy: Result of E7208.
Hochster H, Catalano P, O'Dwyer P, Mitchell E, Cohen D, Faller B, Kortmansky J, Kircher S, Lacy J, Lenz H, Verma U, Benson A. Randomized trial of irinotecan and cetuximab (IC) versus irinotecan, cetuximab and ramucirumab (ICR) as 2nd line therapy of advanced colorectal cancer (CRC) following oxaliplatin and bevacizumb based therapy: Result of E7208. Journal Of Clinical Oncology 2018, 36: 3504-3504. DOI: 10.1200/jco.2018.36.15_suppl.3504.Peer-Reviewed Original Research
2014
Interim analysis of a phase II study of dose-modified FOLFIRINOX (mFOLFIRINOX) in locally advanced (LAPC) and metastatic pancreatic cancer (MPC).
James E, Yao X, Cong X, Li J, Hahn C, Kaley K, Kortmansky J, Fischbach N, Chang B, Salem R, Cha C, Stein S, Hochster H, Lacy J. Interim analysis of a phase II study of dose-modified FOLFIRINOX (mFOLFIRINOX) in locally advanced (LAPC) and metastatic pancreatic cancer (MPC). Journal Of Clinical Oncology 2014, 32: e15226-e15226. DOI: 10.1200/jco.2014.32.15_suppl.e15226.Peer-Reviewed Original Research
2005
A phase I clinical and pharmacokinetic study of weekly docetaxel followed by flavopiridol: promising activity in metastatic pancreatic cancer
Rathkopf D, Fornier M, Shah M, Kortmansky J, O’Reilly E, Winkelmann J, Balzano L, Kelsen D, Schwartz G. A phase I clinical and pharmacokinetic study of weekly docetaxel followed by flavopiridol: promising activity in metastatic pancreatic cancer. Journal Of Clinical Oncology 2005, 23: 4096-4096. DOI: 10.1200/jco.2005.23.16_suppl.4096.Peer-Reviewed Original ResearchA phase I trial of erlotinib, gemcitabine and radiation for patients with locally advanced, unresectable pancreatic cancer
Kortmansky J, O’Reilly E, Minsky B, Puleio S, Winkelmann J, Kelsen D, Schwartz G. A phase I trial of erlotinib, gemcitabine and radiation for patients with locally advanced, unresectable pancreatic cancer. Journal Of Clinical Oncology 2005, 23: 4107-4107. DOI: 10.1200/jco.2005.23.16_suppl.4107.Peer-Reviewed Original Research
2004
Management of hyperglycemia in patients with metastatic pancreatic cancer receiving UCN-01 and fluorouracil
Kortmansky J, Sauter N, O'Reilly E, Shah M, Abou-Alfa G, Winkelmann J, Yi S, Gonen M, Kelsen D, Schwartz G. Management of hyperglycemia in patients with metastatic pancreatic cancer receiving UCN-01 and fluorouracil. Journal Of Clinical Oncology 2004, 22: 2140-2140. DOI: 10.1200/jco.2004.22.14_suppl.2140.Peer-Reviewed Original ResearchManagement of hyperglycemia in patients with metastatic pancreatic cancer receiving UCN-01 and fluorouracil
Kortmansky J, Sauter N, O'Reilly E, Shah M, Abou-Alfa G, Winkelmann J, Yi S, Gonen M, Kelsen D, Schwartz G. Management of hyperglycemia in patients with metastatic pancreatic cancer receiving UCN-01 and fluorouracil. Journal Of Clinical Oncology 2004, 22: 2140-2140. DOI: 10.1200/jco.2004.22.90140.2140.Peer-Reviewed Original Research